Original Article |
Corresponding author: Milan Jagurinoski ( m.jagurinoski@hematology.bg ) © 2023 Milan Jagurinoski, Yanitsa Davidkova, Milena Stojcov-Jagurinoska, Gueorgui Balatzenko, Branimir Spassov, Margarita Guenova.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation:
Jagurinoski M, Davidkova Y, Stojcov-Jagurinoska M, Balatzenko G, Spassov B, Guenova M (2023) Secondary acute myeloid leukemia and de novo acute myeloid leukemia with myelodysplasia-related changes - close or complete strangers? Folia Medica 65(5): 728-736. https://doi.org/10.3897/folmed.65.e98404
|
Aim: To compare the main features of patients with secondary acute myeloid leukemias (AMLs) after post-myelodysplastic syndrome (AML-post-MDS) or post-myeloproliferative neoplasms (AML-post-MPN) and myeloid blast crisis of chronic myeloid leukemia (CML-BC) vs. de novo AMLs with myelodysplastic characteristics (dn-AML-MDS).
Materials and methods: Bone marrow/peripheral blood samples of 94 patients with secondary AMLs (30 with AML-post-MDS, 20 with AML-post-MPN, and 14 with CML-BC) and 30 with dn-AML-MDS were included. Demographic, morphological, phenotypic, cytogenetic, and survival data were analyzed.
Results: Comparative analysis showed no differences in sex and age, except for the younger age in CML-BC (p=0.005). Leukocytosis was a prevalent feature of CML-BC vs. AML-post-MPN, AML-post-MDS and dn-AML-MDS (p<0.001). At leukemia onset, thrombocytopenia was characteristic of AML-post-MDS and dn-AML-MDS whereas normal PLT counts were found in AML-post-MPN and CML-BC (p=0.001). Dysplasia in ≥2 lineages was observed in almost all dn-AML-MDS (96.8%) and AML-post-MDS (100%) compared to AML-post-MPN (33.3%) and none of the CML-BC (p=0.001). Aberrant co-expression of 1-4 lymphoid-associated markers was detected in 67.5% of all patients, including CD7, CD19, CD56, and CD22. We found chromosome aberrations in 57.8% of patients, more frequently in dn-AML-post-MDS than in AML-post-MPN, CML-BC, and AML-post-MDS. While NPM1 mutations distribution was similar in the two MDS-related AML groups, FLT3-ITD was higher in AML-post-MDS (26.3%) than in dn-AML-MDS (4.5%) (p=0.049). Regarding EVI1, CML-BC (80%) and AML-post-MPN (37.5%) showed higher incidence of gene overexpression compared to AML-post-MDS (13.3%) and dn-AML-MDS (5.0%) (p=0.001). Median time to leukemia was significantly shorter in AML-post-MDS (4.80±1.04 months) than in AML-post-MPN (20.3±2.86 months) and CML-BC (34.7±16.3 months) (p=0.008), and median overall survival was poor in all groups.
Conclusions: Similarities and differences between patients with secondary AMLs may represent different biology which translates into different clinical course and may require different therapeutic approach in future.
acute myeloid leukemia, blast crisis, myelodysplasia, myeloproliferative disorder
AMLs acute myeloid leukemias
AML-post-MDS post-myelodysplastic syndrome
AML-post-MPN post-myeloproliferative neoplasms
CML-BC myeloid blast crisis of chronic myeloid leukemia
dn-AML-MDS de novo AMLs with myelodysplastic charac-teristics
PLT platelet count
MDS myelodysplastic syndrome
PB peripheral blood
BM bone marrow
sAML secondary acute myeloid leukemia
LT leukemic transformation
MPN myeloproliferative neoplasms
CML chronic myeloid leukemia
TKI tyrosine kinase inhibitors
TTL time to leukemia
OS overall survival
AM lymphoid-associated markers
Acute myeloid leukemia (AML) is a malignant hematologic disease resulting from clonal expansion of myeloid blasts ≥20% in peripheral blood (PB) and/or bone marrow (BM). It is a heterogeneous category in terms of morphology, genetic characteristics, and clinical presentation. Disease can occur de novo in cases in which it arises without an identified prior stem cell disorder or proven leukemogenic exposure; or as secondary (sAML) to a prior hematologic disorder with potential for leukemic transformation (LT), such as myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).[
The natural history of myeloproliferative neoplasms, both Ph(+) chronic myeloid leukemia (CML) and Ph(−) MPNs, has been well documented, but the mechanism underlying progression from an initial, rather indolent chronic phase to an advanced phase remains obscure. The risk of transformation in CML to a blast crisis (CML-BC) in the tyrosine kinase inhibitors (TKI) era appears to be quite low (<2% per year). Approximately 4%-6% of patients diagnosed with MPN transform into AML (AML-post-MPN).[
About one-third of patients with MDS transform into AML.[
In general, AMLs evolving from an antecedent hematological disorder or bearing dysplastic morphological and/or genetic features without a clear history of prior disease tend to be difficult to manage and are associated with a poor prognosis. Although distinct categories are tied to different biologic processes, the malignant clones demonstrate similar phenotypes, common clinical presentation after LT and are frequently insensitive to traditional AML chemotherapeutic agents. Current classification introduces some overlapping and confusing criteria resulting in highly heterogeneous entities, which makes the understanding of the specific nature of this clinical convergence and the introduction of biologically relevant management approaches difficult.
Therefore, we aimed at a comparative study of patients with AMLs developed through different pathways – de novo, post-MDS, post-MPN, and CML, regarding their major clinical and laboratory characteristics, genetic aberrations, and outcomes.
This study included 94 adult patients diagnosed and treated at Sofia’s National Hematology Hospital over a 5-year period, including 55 male and 39 female patients with a median age of 61±44.7 years (range, 26-89 years). Informed consent according to the criteria of the local ethical commission was obtained. Diagnosis was based on an integrated assessment of clinical, morphological, immunophenotypic and genetic features according to WHO classification criteria for 2016[
Demographic data, main hematological parameters (Hgb, WBC, PLT), blasts % and dysplasia in hematopoietic populations in BM and/or PB samples at diagnosis were evaluated. Complete blood counts and microscopic differential counts of May-Grünwald-Giemsa-stained BM samples were performed.
Immunophenotyping of leukemic cells from BM and/or PB was performed using a panel of fluorochrome-labeled antibodies recommended by Euro Flow: CD1a, CD2, cyCD3, sCD3, CD4, CD5, CD7, CD8, CD9, CD10, CD11b, CD13, CD14, CD15, CD16, CD19, CD20, CD21, CD22, CD24, CD25, CD33, CD34, CD35, CD36, CD38, CD44, CD45, CD45RA, CD56, CD58, CD64, CD66c, CD71, cyCD79a, CD81, CD99, CD105, CD117, CD123, CD203c, CD300e, HLADR, NG2, TCRαβ, cyTCRβ, TCRγδ, cyIgμ, sIgκ, sIgλ, sIgM, NuTdT, cyMPO.[
Chromosome G-banding was successful in 65 BM samples. Karyotypes were described according to the International System for Human Cytogenetic Nomenclature criteria 2016.[
Additional molecular analysis of FLT3-ITD, NPM1 mutations and EVI1 gene overexpression were performed using polymerase chain reaction-based assays.
The following therapy was administered: 79 (84.1%) received chemotherapy, including idarubicin/cytarabine-based ‘7+3’ regimen (n=27), ‘cytarabine + mitoxantrone + etoposide’ (n=8), cytarabine monotherapy (n=21), ‘idarubicin + cytarabine + imatinib’ (n=11), and ‘cytarabine + imatinib’ (n=3). Nine patients were treated with hypomethylating agents. The remaining 15.9% were treated with supportive care alone, including the use of hydroxyurea to control leukocytosis. Five of the patients received allogeneic stem cell transplantation.
Standard statistical methods were used to determine significance of differences among groups in distribution of continuous or nominal variables. Time to leukemia (TTL) was evaluated from diagnosis to LT. Overall survival (OS) was calculated from time of AML diagnosis until death. Estimation of the OS was done using Kaplan-Meier method and compared by the log-rank test. Reported differences at p<0.05 were accepted as statistically significant (SPSS v. 23, Stat soft Inc., Los Angeles, CA, USA).
Demographic data analysis revealed that mean age of patients with AML-post-MPN, AML-post-MDS and dn-AML-MDS was in the sixth decade (64.8±10.5 years, 61.2±16.9 years, and 62.8±13.9 years, respectively) and was higher compared to that of CML-BC patients (49.2±14.1 years, p=0.005), with a male predominance in all disease entities. Major clinical and laboratory characteristics of patients are shown in Table
dn-AML-MDS n=30) | AML-post-MDS (n=30) | AML-post-MPN (n=20) | CML-BC (n=14) | p value | |
Demographic parameters | |||||
Male:female | 1.14:1 | 1.64:1 | 1.44:1 | 1.6:1 | NS |
Age, (years) (mean±SD) | 64.4±11.9 | 62±16.6 | 63.4±11.5 | 46.9±13.8 | 0.005 |
Hematological indexes | |||||
Hgb, (g/L) (mean±SD) | 81.3±18.2 | 82.2±15.6 | 84.4±20.5 | 78.9±20.3 | NS |
WBC, (×109/L) (mean±SD) | 15.5±33.8 | 26.3±43.3 | 73.1±81.4 | 133.2±154.5 | <0.001 |
PLT, (×109/L) (mean±SD) | 92.5±107.8 | 75.3±102.3 | 156.4±188.4 | 278.1±241.8 | 0.001 |
Bone marrow morphology | |||||
% blasts (mean±SD) | 42.4±17.4 | 45.8±21.5 | 55.1±25.6 | 29.8±17.4 | NS |
Dysgranulocytopoiesis, (%) | 96.55% | 61.54% | 44.44% | 20.00% | <0.001 |
Dyserythropoiesis, (%) | 48.28% | 57.69% | 22.20% | 0.00% | NS |
Dysmegakaryocytopoiesis, (%) | 72.41% | 61.54% | 55.55% | 20.00% | NS |
Dysplasia in >2 cell lineages, (%) | 96.55% | 100.00% | 33.33% | 0% | <0.001 |
Phenotype | |||||
CD13, (% pos. pts) | 93.33% | 88.46% | 75.00% | 81.82% | NS |
CD33, (% pos. pts) | 93.33% | 88.46% | 93.75% | 100.00% | NS |
CD64, (% pos. pts) | 50.00% | 34.62% | 25.00% | 9.09% | NS |
CD117, (% pos. pts) | 100.00% | 88.46% | 93.75% | 100.00% | NS |
MPO, (% pos. pts) | 53.33% | 42.31% | 25.00% | 36.36% | NS |
Lymphoid-associated markers, (% pos. pts) | 70.00% | 65.39% | 50.00% | 90.91% | NS |
>2 lymphoid-associated markers, (% pos. pts) | 36.67% | 26.93% | 37.50% | 45.46% | NS |
Cytogenetic and molecular aberrations | |||||
Normal karyotype, (% pts) | 25% (6/24) | 58.3% (14/24) | 33.3% (2/6) | 42.2% (5/11) | NS |
Aberrant karyotype, (% pts) | 75% | 41.7% | 66.7% | 57.8% | NS |
Complex karyotype, (% pts) | 45.8% (11/24) | 20.8% (5/24) | 50% (3/6) | 0% | 0.05 |
Unbalanced abnormalities | 16.7% (4/24) | 20.8% | 16.7% (1/6) | 40.0% (4/10) | 0.05 |
Balanced abnormalities | 12.5% (3/24) | 0% | 0% | 10.0% (1/10) | 0.05 |
Chromosome 5, (% pts) | 40.0% | 29.2% | 33.3% | 0.00% | 0.053 |
Chromosome 7, (% pts) | 36.0% | 8.3% | 0.00% | 0.00% | 0.012 |
FLT3-ITD, (% pts) | 4.5% | 26.3% | 25.0% | NA | 0.049* |
EVI1 overexpression, (% pts) | 5.0% | 13.3% | 37.5% | 80.0% | 0.001 |
NPM1 mutation, (% pts) | 9.5% | 20.0% | 50.0% | NA | NS |
Clinical course | |||||
TTL months, (median±SD) | NA | 4.80±1.0 | 20.3±2.9 | 34.7±16.3 | 0.008 |
OS months (median±SD) | 6.17±2.77 | 4.17±0.77 | 5.17±2.79 | 13.67±4.58 | NS |
Аs to hematological parameters, all patients in our study were anemic, and no differences in their Hgb levels were observed. Leukocytosis was more common in CML-BC (133.2±154.5×109/L) compared to AML-post-MPN (73.1±81.4×109/L), AML-post-MDS (26.3±43.3×109/L), and dn-AML-MDS (15.6±32.8×109/L) patients (p<0.001). Patients with AML-post-MDS and dn-AML-MDS were characterized with thrombocytopenia at leukemia onset whereas mean PLT counts were within reference ranges in AML-post-MPN and CML-BC patients (75.3±102.3×109/L; 91.0±103.7×109/L vs. 156.4±188.4×109/L; 278.1±241.8×109/L, respectively, p=0.001).
In terms of tumor burden, no significant differences were found in BM blasts % between groups with an average of 45% leukemic infiltration. However, estimation of morphology showed various patterns of dysplasia. Dysplastic changes in ≥2 lineages occurred in none of the CML-BC patients and only in 33.3% of the AML-post-MPN patients, as opposed to the dn-AML-MDS patients (96.8%) and AML-post-MDS patients (100%) (p=0.001). Granulocytic and megakaryocytic cells were mostly affected while no significant differences were found in erythroid series (Table
Immune phenotype of blast cells was immature myeloid defined by ≥2 myeloid-associated markers, e.g., CD33 (92.8%), CD13 (86.7%), myeloperoxidase (42.2%), CD64 (34.9%), CD14 (12.0%), as well as by immature markers CD34 (80.7%) and CD117 (95.2%) (Table
Chromosomal aberrations were found in 57.8% of patients. The most frequently involved chromosomes were 5 (29.2%); 1 (21.5%); 12 and 17 (18.5% each), and 7 and 11 (16.9% each). The overall incidence of cytogenetic abnormalities and of unbalanced abnormalities, in particular, did not differ between groups, while complex karyotypes were not detected in CML-BC, and balanced abnormalities were seen in only one CML patient and one patient with dn-AML-MDS. In addition, dn-AML-MDS showed the highest frequency of complex karyotypes (45.8%) and aberrations of chromosome 7 (36%) defining a distinctive genetic profile from AML-post-MDS and other sAMLs (Fig.
A) Cytogenetic incidence: aberrant karyotypes including normal did not differ between groups. B) Mutational findings in patient cohort comparing AML-post-MDS vs. dn-AML-MDS with significant difference regarding FLT3-ITD mutation.
The molecular pattern also differed within the groups. EVI1 overexpression was found during LT in a considerable proportion of CML-BC (80%) and AML-post-MPN (37.5%) patients, while it was less frequent in AML-post-MDS (13.3%) and dn-AML-MDS (5%) patients (p=0.001). NPM1 mutations distribution was similar in the two MDS-related AML groups, while FLT3-ITD was higher in AML-post-MDS (26.3%) compared to dn-AML-MDS (4.5%) (p=0.049) (Fig.
The median TTL was significantly shorter in AML-post-MDS (4.80±1.04 months) than in AML-post-MPN (20.3±2.86 months) and CML-BC (34.7±16.3 months) (p=0.008) (Fig.
Comparison of the TTL in patients with sAML and CML-BC and the OS in the entire cohort. A) The median TTL is significantly shorter in AML-post-MDS (4.80±1.0 months) than in AML-post-MPN (20.3±2.9 months) and the longest in CML-BC (34.7±16.3 months) (Kaplan Meyer log rank test, p=0.008); B) No difference in the OS (Kaplan Meyer log rank test, p=0.355) despite the fact that CML-BC patients (median OS 13.67±4.58 months) tended to have the longest OS compared with the dn-AML-MDS (median OS 6.17±2.77 months) and sAMLs groups (median OS in AML-post-MDS, 4.17±0.7 months; median OS in AML-post-MPN 7 5.17±2.79 months).
To our knowledge, no study has been published to date directly comparing hematological parameters at diagnosis of sAMLs developing on the basis of Ph(+)/Ph(-)MPN and MDS with dn-AML-MDS. As expected, our data clearly demonstrated significantly higher platelet counts and leukocytosis in sAML-post-MPN/CML-BC, in comparison with AML-MDS either de novo or secondary to MDS. Thus, the upregulated proliferation, which is a hallmark of MPNs, appears to be an essential mechanism also in LT after MPN/CML, which is in line with other authors.[
Morphological dysplasia is currently an important aspect of the discussion. It is a key characteristic of AML cases currently classified as AML-MDS, which is a heterogeneous group comprising de novo and secondary cases. As expected, we also found a significantly higher incidence of dysplastic changes in ≥2 lineages in both categories. However, evidence has recently showed that AML-MDS defined only by morphological findings may not represent a poor prognosis AML.[
Immunophenotypic aberrancies such as the co-expression of LAM are still doubtable and most of the studies lack detailed subgroup analysis reflecting the secondary nature of AML.[
Apart from the impact of chromosomal abnormalities, the development of AML is driven by somatic mutations resulting in the clonal expansion of stem cells. In this connection, we investigated the distribution of some of the most relevant gene mutations in AML diagnosis. FLT3 are one of the commonest, and clinically challenging, class of AML mutations. In general, they are detected in about twenty-five of dn-AML and are associated with increased relapse and inferior OS.[
Our data outline the presence of common characteristics, е.g., cytogenetic abnormalities, complex karyotypes, and chromosome 5 aberrations. However, differences could also be observed, e.g., prevalence of proliferation patterns, EVI1-overexpression, and lack of chromosome 7 aberrations in post-Ph(+)/Ph(-)MPN leukemias, FLT3-ITD patterns in dn-AML and sAMLs, etc.
Differences may underlie variations in the observed time to overt leukemia presentation which in our study is consistent with published data.[
Our study has certain limitations, such as the retrospective design and the low number of patients in the separate categories compared. However, it clearly demonstrates similarities and differences among these four entities, which reflect the biological heterogeneity of diseases. Understanding the pathogenetic mechanisms may allow us to apply different preventive and/or therapeutic approaches in the future, and it is worth conducting further studies to investigate.
The authors have no support to report.
The authors have no funding to report.
The authors have declared that no competing interests exist.
All authors have contributed equally to this work